Bristol De-Lists ABI Taxol Patent Under Settlement With Ivax
Executive Summary
Bristol-Myers Squibb is de-listing the American BioSciences paclitaxel patent that threatened the continued marketing of generic versions of Taxol
You may also be interested in...
Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA
Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA